PubRank

P T Dawes

Author PubWeight™ 99.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 2.19
2 Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001 1.70
3 Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology (Oxford) 2000 1.67
4 Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. Br J Rheumatol 1986 1.64
5 Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 1996 1.42
6 Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 1998 1.40
7 The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis. Br J Rheumatol 1991 1.25
8 HLA-DRB1 alleles encoding an aspartic acid at position 70 protect against development of rheumatoid arthritis. J Rheumatol 2001 1.25
9 The reliability of the three-dimensional FASTRAK measurement system in measuring cervical spine and shoulder range of motion in healthy subjects. Rheumatology (Oxford) 2000 1.19
10 Radiographic patterns and response to corticosteroid hip injection. Ann Rheum Dis 1997 1.18
11 Coeliac disease presenting as recurrent pericarditis. Lancet 1981 1.18
12 Anti-rheumatic drugs and joint damage in rheumatoid arthritis. Q J Med 1985 1.17
13 Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. Arthritis Rheum 2001 1.17
14 Clinical value of ELISA assays for IgM and IgG rheumatoid factors. J Clin Pathol 1987 1.15
15 Transforming growth factor beta 1 and interleukin 4 induced alpha smooth muscle actin expression and myofibroblast-like differentiation in human synovial fibroblasts in vitro: modulation by basic fibroblast growth factor. Ann Rheum Dis 1997 1.14
16 Prediction of progressive joint damage in patients with rheumatoid arthritis receiving gold or D-penicillamine therapy. Ann Rheum Dis 1986 1.11
17 Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 1996 1.10
18 Serum matrix metalloproteinase 3 as a predictor of joint destruction in rheumatoid arthritis: comment on the article by Yamanaka et al. Arthritis Rheum 2000 1.07
19 The GALS locomotor screen and disability. Ann Rheum Dis 1993 1.07
20 Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol 1989 1.04
21 Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope. Ann Rheum Dis 1999 1.01
22 Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation. Eur J Clin Pharmacol 1986 1.01
23 Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994 1.01
24 Gonococcal arthritis: an unusual presentation as pseudothrombophlebitis. Ann Rheum Dis 1985 1.00
25 Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994 0.99
26 Spontaneous haemarthrosis following thrombolytic therapy for myocardial infarction. Postgrad Med J 1990 0.97
27 Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 2002 0.96
28 Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 2004 0.95
29 High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis. J Rheumatol 2000 0.95
30 How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clin Rheumatol 2000 0.94
31 Tissue typing in brucellosis. Ann Rheum Dis 1985 0.94
32 Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) 2005 0.94
33 Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 2002 0.93
34 Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun 2004 0.92
35 Medical audit: the differing perspectives of managers and clinicians. J R Coll Physicians Lond 1992 0.92
36 Development and preliminary assessment of a simple measure of overall status in rheumatoid arthritis (OSRA) for routine clinical use. QJM 1995 0.90
37 Primary care--the educational need. Br J Rheumatol 1990 0.90
38 Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 1991 0.89
39 Demonstration of cytokeratin in endothelial cells of the synovial microvasculature in situ and in vitro. Br J Rheumatol 1993 0.87
40 Massive eosinophilia in rheumatoid arthritis: report of four cases. Clin Rheumatol 1986 0.87
41 Comparison and evaluation of a disease activity index for use in patients with rheumatoid arthritis. Br J Rheumatol 1990 0.86
42 Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study. Br J Rheumatol 1989 0.86
43 Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis. Ann Rheum Dis 2005 0.86
44 Influence of variations across the MMP-1 and -3 genes on the serum levels of MMP-1 and -3 and disease activity in rheumatoid arthritis. Genes Immun 2011 0.86
45 Comparison of IgA-alpha1-antitrypsin levels in rheumatoid arthritis and seronegative oligoarthritis: complex formation is not associated with inflammation per se. Br J Rheumatol 1998 0.86
46 Multiple joint avascular necrosis: beware of tuberculosis and human immunodeficiency virus--a rare but important cause. Br J Rheumatol 1995 0.86
47 Self-referral of symptoms (SOS) follow-up system of appointments for patients with uncertain diagnoses in rheumatology out-patients. Rheumatology (Oxford) 2005 0.85
48 Radiological assessment of outcome in rheumatoid arthritis. Br J Rheumatol 1988 0.85
49 Improving the response to gold or D-penicillamine by addition of sulphasalazine. A pilot study in 25 patients with rheumatoid arthritis. Clin Exp Rheumatol 1987 0.85
50 An unusual case of adult varicella-associated arthritis. Rheumatology (Oxford) 2000 0.85
51 Soluble adhesion molecules and anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. J Rheumatol 1999 0.84
52 Rheumatoid arthritis and chronic lymphatic leukaemia. Clin Exp Rheumatol 1990 0.84
53 Association between cigarette smoking and release of tumour necrosis factor alpha and its soluble receptors by peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006 0.84
54 The relationship between serial measures of disease activity and outcome in rheumatoid arthritis. Q J Med 1993 0.84
55 Sterno-costo-clavicular hyperostosis. Br J Clin Pract 1992 0.83
56 Enthesopathy index in ankylosing spondylitis. Ann Rheum Dis 1987 0.83
57 The development of three-dimensional range of motion measurement systems for clinical practice. Rheumatology (Oxford) 2001 0.82
58 Interaction between tumor necrosis factor microsatellite polymorphisms and the HLA-DRB1 shared epitope in rheumatoid arthritis: influence on disease outcome. Arthritis Rheum 1999 0.82
59 The mechanical joint score: a new clinical index of joint damage in rheumatoid arthritis. Rheumatology (Oxford) 2002 0.82
60 Should disease-modifying agents be used in mild rheumatoid arthritis? Br J Rheumatol 1991 0.81
61 Rheumatoid arthritis: an association with pemphigus foliaceous. Acta Derm Venereol 1992 0.81
62 Increased IgA antibodies to cytokeratins in the spondyloarthropathies. Ann Rheum Dis 1994 0.81
63 Why not use OSRA? A comparison of Overall Status in Rheumatoid Arthritis (RA) with ACR core set and other indices of disease activity in RA. J Rheumatol 1998 0.81
64 Acute knee joint rupture--a report of two unusual cases. Br J Rheumatol 1983 0.81
65 Prediction of radiographic damage in hands and feet in rheumatoid arthritis by clinical evaluation. Clin Rheumatol 1994 0.81
66 ELISA assays for IgM and IgG rheumatoid factors: their clinical correlations during therapy with slow-acting anti-rheumatic drugs. Clin Rheumatol 1987 0.81
67 Increased levels of IgA antibodies to cytokeratin-18 and epidermal keratin in rheumatoid arthritis. Arthritis Rheum 1993 0.80
68 Influence of polymorphism in the manganese superoxide dismutase locus on disease outcome in rheumatoid arthritis: evidence for interaction with glutathione S-transferase genes. Arthritis Rheum 2000 0.80
69 Saline washout for knee osteoarthritis: results of a controlled study. Clin Rheumatol 1987 0.80
70 Small joint synovitis in rheumatoid arthritis: should it be assessed separately? Br J Rheumatol 1995 0.80
71 Abnormal IgA levels in patients with rheumatoid arthritis. Ann Rheum Dis 2003 0.79
72 Acute synovial rupture in Behçet's syndrome. Ann Rheum Dis 1983 0.79
73 Suspected cutaneous drug toxicity in rheumatoid arthritis--an evaluation. Br J Rheumatol 1993 0.79
74 Polyarthritis, rash and lymphadenopathy: case reports of two patients with angioimmunoblastic lymphadenopathy presenting to a rheumatology clinic. Clin Rheumatol 1998 0.79
75 A disease activity index: its use in clinical trials and disease assessment in patients with rheumatoid arthritis. Semin Arthritis Rheum 1993 0.78
76 The effects of Tenidap on cytokine induced proliferation of human synovial fibroblasts in vitro. Ann Rheum Dis 1994 0.78
77 The overall status in rheumatoid arthritis (OSRA) measure--further evidence to support its use in clinical practice. Rheumatology (Oxford) 2007 0.78
78 Measurement of natural killer cell cytotoxicity by area under a cytotoxic curve. A method suitable for rheumatoid arthritis. J Immunol Methods 1988 0.78
79 Intra-bursal tetracycline in the treatment of olecranon bursitis in patients with rheumatoid arthritis. Br J Rheumatol 1994 0.78
80 Painful knees associated with a septic focus. Br J Rheumatol 1995 0.78
81 Raised endothelial cell stimulating angiogenesis factor in ankylosing spondylitis. Clin Exp Rheumatol 1994 0.78
82 The influence of HLA-DRB1 alleles encoding the DERAA amino acid motif on radiological outcome in rheumatoid arthritis. Rheumatology (Oxford) 1999 0.78
83 The utility of the 1987 revised ARA criteria for rheumatoid arthritis in early synovitis. Br J Rheumatol 1991 0.77
84 Control perceptions in patients with rheumatoid arthritis: the role of social support. Musculoskeletal Care 2003 0.77
85 Monitoring of rheumatoid arthritis. Lancet 1989 0.77
86 Oxidation of alpha1-proteinase inhibitor by the myeloperoxidase-hydrogen peroxidase system promotes binding to immunoglobulin A. Biochem Biophys Res Commun 1999 0.77
87 Anti-ganglioside antibodies in patients with rheumatoid arthritis complicated by peripheral neuropathy. Br J Rheumatol 1996 0.77
88 Pityriasis rosea and discoid eczema: dose related reactions to treatment with gold. Ann Rheum Dis 1992 0.77
89 Management of oral complications of disease-modifying drugs in rheumatoid arthritis. Br J Rheumatol 1997 0.77
90 Antinuclear antibodies are associated with tumor necrosis factor receptor I gene polymorphism in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011 0.76
91 Rifampicin in early rheumatoid arthritis. Scand J Rheumatol 1993 0.76
92 Septic polyarthritis due to bacteroides fragilis in a patient with rheumatoid arthritis. Clin Rheumatol 1984 0.76
93 Human parvovirus B19 and rheumatoid arthritis. Clin Rheumatol 1992 0.76
94 Antibodies to neuroblastoma cells in rheumatoid arthritis: a potential marker for neuropathy. Clin Exp Rheumatol 2000 0.76
95 The therapeutic response to D-penicillamine in rheumatoid arthritis: influence of glutathione S-transferase polymorphisms. Rheumatology (Oxford) 1999 0.76
96 Calculating radiological progression in rheumatoid arthritis. Clin Rheumatol 1986 0.76
97 Intra-articular steroids: confounder of clinical trials. Clin Rheumatol 1991 0.75
98 Attempts to apply curve fitting models to the analysis of progression of radiographic damage in rheumatoid arthritis are laudable, but are the results believable? J Rheumatol 1995 0.75
99 Measurement of IgA-alpha 1-antitrypsin complex in rheumatoid arthritis: a question of specificity? Ann Rheum Dis 1997 0.75
100 Focal myositis: another cause of pseudothrombophlebitis. Br J Rheumatol 1994 0.75
101 Natural killer cell cytotoxicity and alpha-interferon in early rheumatoid arthritis. Scand J Rheumatol 1993 0.75
102 Spondyloarthropathies and IgA deficiency. Ann Rheum Dis 1991 0.75
103 Interleukin-2 production in early rheumatoid arthritis. Clin Rheumatol 1993 0.75
104 Measures of pain and disease activity in rheumatoid arthritis. Br J Rheumatol 1993 0.75
105 Recognition of complement factor H by a monoclonal antibody used for "specifically" measuring IgA-alpha 1 antitrypsin complexes. Clin Exp Rheumatol 1997 0.75
106 Assessment of ankylosing spondylitis. Br J Rheumatol 1992 0.75
107 Serum pro-matrix metalloproteinase 3 in rheumatoid arthritis: a reflection of local or systemic inflammation? Arthritis Rheum 1996 0.75
108 Inactive alpha 1 antitrypsin in rheumatoid synovial fluid: oxidation, proteolysis, or complex formation? Ann Rheum Dis 1992 0.75
109 Elevated plasma stromelysin levels in arthritis. J Rheumatol 1995 0.75
110 Increased levels of antibodies to cytokeratin 18 in patients with rheumatoid arthritis and ischaemic heart disease. Ann Rheum Dis 2004 0.75
111 Yersinia arthritis with erythema nodosum. Postgrad Med J 1986 0.75
112 Autoantibodies to nuclear lamins and to intermediate filament proteins. J Rheumatol 1993 0.75
113 Circulating levels of matrix metalloproteinases in rheumatic diseases. J Rheumatol 1999 0.75
114 Persistent monoarthritis and occult coeliac disease. Postgrad Med J 1994 0.75
115 The clinical terms project. Br J Rheumatol 1992 0.75
116 Is misonidazole induced neurotoxicity permanent. Int J Radiat Oncol Biol Phys 1988 0.75
117 Olecranon bursitis related to calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 1983 0.75
118 An index of disease activity in rheumatoid arthritis. Stat Med 1993 0.75
119 Availability of non-steroidal anti-inflammatory drugs over the counter: information needed. Br Med J (Clin Res Ed) 1984 0.75
120 Clinically significant vitamin C deficiency in rheumatoid arthritis. Br J Rheumatol 1985 0.75
121 Quantitative radio-isotope scanning in ankylosing spondylitis: a clinical, laboratory and computerised tomographic study. Scand J Rheumatol 1991 0.75
122 Haemarthrosis due to ascorbic acid deficiency. Br J Clin Pract 1985 0.75
123 Persisting aluminium-related bone disease after cadaveric renal transplantation. Nephrol Dial Transplant 1999 0.75
124 The importance of endoscopy in rheumatology: results of a comparative study between a group of arthritic patients and controls. Br J Clin Pract 1987 0.75
125 Prevalence of antibodies to neurofilament polypeptides in patients with rheumatoid arthritis complicated by peripheral neuropathy. Clin Exp Rheumatol 1999 0.75
126 Sacroiliitis in an HLA B27-negative patient following giardiasis. Br J Rheumatol 1998 0.75
127 Raised epidermal phospholipase A2 activity in rheumatoid arthritis. Clin Exp Rheumatol 1991 0.75
128 Combination therapy in rheumatoid arthritis--study design. Br J Rheumatol 1987 0.75
129 Capillaritis: a manifestation of rheumatoid disease. Clin Rheumatol 1993 0.75
130 Use of the Stoke Index to differentiate between disease-modifying agents and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Exp Rheumatol 1994 0.75
131 TNF therapy for spondyloarthropathy: can we marshal the argument? Rheumatology (Oxford) 2004 0.75
132 An unhappy outlook for drug therapy. Lancet 1984 0.75
133 Osmosin: its effect on plasma and synovial fluid kinetics of indomethacin. Eur J Clin Pharmacol 1985 0.75
134 Right-sided endocarditis complicating prolonged central venous catheterisation. Intensive Care Med 1981 0.75
135 The association and predictive value of the complex immunoglobulin A-alpha 1-antitrypsin in the development of erosions in early rheumatoid arthritis. Scand J Rheumatol 1991 0.75
136 Comparison of IgA-alpha 1-antitrypsin levels in rheumatoid and reactive arthritis. Biochem Soc Trans 1997 0.75
137 Yersinia-related arthritis in the United Kingdom. A report of 12 cases and review of the literature. Q J Med 1992 0.75
138 Synovial sarcoma manifesting as a single joint flare in rheumatoid arthritis. Clin Rheumatol 1993 0.75
139 The importance of gastrointestinal symptoms in arthritic patients. Br J Rheumatol 1986 0.75
140 Short-term effects of antirheumatic drugs. Baillieres Clin Rheumatol 1992 0.75
141 Visiting other departments. Br J Rheumatol 1991 0.75
142 Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus. Clin Rheumatol 1994 0.75